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systematic review of randomized-comparative clinical trials was performed to deter-
mine the effects and risks associated with the degree of hemoglobin/hematocrit (Hgb/
Hct) level variability outside the recommended range. Diagnostic algorithm and guides 
treatment adaptation were built out of a panel of experts. Resource use and costs data 
were obtained from the Instituto Mexicano del Seguro Social (IMSS). The costs and 
effectiveness were discounted annually at 3%. The threshold to deﬁne a therapy as 
cost-effective was ﬁxed at USD$25,020.00 (least than three times Mexican GDP per 
capita) following the recommendations of WHO’s Commission on Macroeconomics 
and Health. RESULTS: The clinical success rate (patients within 11–12.5 Hbg/dl 
levels) when using C.E.R.A. vs EPO-alpha showed signiﬁcant difference (86.79% 
[95% CI, 84.70%–88.88%] vs 50.48% [95% CI, 47.38%–53.58%] respectively, 
p  0.0001). The treatment care cost per year for C.E.R.A. was US$2,776.13 
(95%CI,US$2,740.9–US$2,811.43) vs US$2,907.88 (95%CI,US$2,883.27–US$2,932.47) 
for EPO-Beta, (p  0.0001); and the hospitalization cost USD$7,089.74 vs 
US$11,255.09 for each one. C.E.R.A. therapy reduces the cost of RA treatment in 
CKD at a 4.53% compared to EPO-alpha therapy and reduced in 37% the hospital 
stay due to Hgb/Hct levels variation. The Cost-effectiveness plane indicates that 
C.E.R.A. is a highly cost-effective therapy; with a probability of 0.60 to be cost saving 
and 0.99 of probability of being cost effective at a USD$4,450 threshold (less than 
one Mexican PIB per capita). CONCLUSIONS: This results show that the use of 
C.E.R.A. for the treatment of RA in patients with CKD is cost-effective.
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OBJECTIVES: The addition of rituximab to cyclophosphamide, vincristine and pred-   
nisolone (R-CVP) signiﬁcantly improved time-to-progression by 17 months in patients         
with previously untreated advanced follicular lymphoma (Marcus et al, 2008). Based      
on these results, we evaluated the clinical outcomes and cost-effectiveness of R-CVP 
versus CVP alone from the perspective of the Romanian National Health Insurance 
House and Ministry of Health. METHODS: A Markov model with a 10-year time 
horizon was developed based on the randomized controlled trial reported by Marcus 
et al. (2008). Rates of disease progression were derived from the PFS Kaplan-Meier 
curves, mortality rates were obtained from the Scotland-Newcastle Lymphoma Group 
database and Romanian age-speciﬁc mortality tables. The duration of the treatment 
effect of rituximab was conservatively applied for the period of clinical trial follow-up 
(90 months) (hazard ratio  0.468). Direct costs included: drug acquisition costs 
(maximum price from Romanian drugs list 2008), hospitalization costs taken from 
NSPHHSM and NHIH (2008) and calculated based on the tariff per chemotherapy 
administration episode, and post-treatment surveillance costs. Costs were discounted 
by 6.0% p.a. RESULTS: This analysis showed that for each FL treatment where R-
CVP is used instead of CVP, the average beneﬁt to the patient would be an additional 
0.983 life years gained (LYG), and 0.931 years when quality-adjusted (QALY). Drug 
acquisition costs were higher with rituximab, however, this was partially offset by 
lower costs for progression. When R-CVP is compared to CVP alone, the incremental 
cost per LYG or QALY gained was calculated as a7155 and a7557, respectively. 
Sensitivity analyses indicated these results were sensitive to the time horizon (longer 
the time horizon, lower the cost per QALY gained) and that the model was robust. 
CONCLUSIONS: This study conﬁrms the long-term clinical and economic beneﬁts of 
adding rituximab to CVP in patients with FL in Romania.
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OBJECTIVES: The rising incidence of invasive fungal infections (IFI), especially inva-
sive aspergillosis, compromises therapeutic outcomes in haematologic cancer patients 
and in transplant recipients.The aim of our analysis was to determine the cost-
 effectiveness of prophylaxis with posaconazole in comparison with standard azole 
therapy (ﬂuconazole or itraconazole) for risk haematology patients in Czech Republic. 
METHODS: The decision-tree economic model was developed for patients with acute 
myelogenous leukemia (AML). The rates of IFI, IFI-related mortality, overall mortality 
and treatment duration were obtained from randomised controlled trials.The cost of 
drugs and IFI hospitalisation was obtained from panel of experts. The model estimates 
total costs, numbers of IFIs, and life-years gained (LYG) per patient in each prophy-
laxis group. Cost and health effects were discounted at 3%. RESULTS: In comparison 
with ﬂuconazole/itraconazole prophylaxis, posaconazole prophylaxis was associated 
with signiﬁcant reduction in the rates of IFI in AML patients, lower IFI-related deaths 
and increased life years. Accumulated cost to the Czech health care system per patient 
receiving the posaconazole regimen was a2770 compared to a2090 for the ﬂucon-
azole/itraconazole regimen. This results in an incremental cost of a680 per patient. 
Incremental life-years saved were 0.016 per patient. The corresponding incremental 
cost effectiveness ratio (ICER) is a42,122 per LYG. Probabilistic sensitivity analysis 
tested numerous assumptions about the model cost and efﬁcacy parameters and found 
that the results were robust to most changes. CONCLUSIONS: In addition to the 
proven efﬁcacy, posaconazole appeared to be cost-effective relative to ﬂuconazole/itra-
conazole in the prophylaxis of IFIs among patients with AML in the settings of Czech 
Republic health care.
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BACKGROUND: Iron deﬁciency and anaemia is common in patients with chronic          
diseases, e.g. chronic kidney disease (CKD), cancer, inﬂammatory bowel disease (IBD), 
and congestive heart failure (CHF) and in connection with large blood losses. One 
appropriate treatment options is intravenous (IV) iron. In Sweden, the Dental and 
Pharmaceutical Beneﬁts Agency, TLV, decides if a medicine should be included in the 
pharmaceutical beneﬁts scheme. TLV makes decisions regarding new products and 
reviews all pharmaceuticals given reimbursement status before 2002. There are three 
IV iron products in Sweden; Ferinject (ferric carboxymaltose), approved for reimburse-     
ment in 2008, and two products approved before 2002: Venofer (iron sucrose) and 
Cosmofer (iron dextran). OBJECTIVES: To present health economic analyses of 
treatment with intravenous iron compared to relevant treatment options in different 
patient populations, i.e. EPO and IV iron vs. EPO and oral iron in CKD, EPO and 
IV iron vs. EPO without iron in cancer, IV Iron vs. no iron in CHF, and IV iron vs. 
oral iron in post-partum and IBD. METHODS: Incremental costs and effects (ICER) 
of IV iron therapy are estimated by comparing relevant treatment alternatives in dif-
ferent patient groups. In CKD, cancer and IBD, model simulations are used. In post-
partum and CHF, a piggyback approach is used. RESULTS: In patients with cancer 
and CKD in dialysis, treatment with IV iron and EPO is found to dominate treatment 
with EPO alone. In IBD patients, intolerant to oral iron, a treatment switch to IV iron 
generated a cost per QALY of a32,377. The ICER for post-partum and CHF patients 
given IV iron compared to oral iron is estimated at a22,280 and a13,850, respectively. 
CONCLUSIONS: The ICER of IV iron treatment compared to relevant alternatives 
is modest for IBD, post-partum and CHF patients and IV iron is dominant for patients 
with haematological cancer and CKD.
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OBJECTIVES: To evaluate the effectiveness and economic consequences of 
treating anemia with original erythropoietic agents in patients with chronic kidney 
disease (CKD) on dialysis and not yet on dialysis. METHODS: The study is a cost-
effectiveness and a cost-minimization analysis based on clinical studies derived from 
the systematic literature search covered Medline and the Cochrane Library. To deter-
mine the economic beneﬁt of using recombinant human erythropoietin (rEPO) agents 
in patients with CKD not on dialysis the comparison between rEPO-A and control 
group were conducted. The cost of rEPO-A, haemodialysis sessions, total days of 
hospitalization, the frequency and the cost of treatment of myocardial infarction were 
taken into account. Cost-minimization analysis were conducted among original eryth-
ropoietic agents (rEPO-A, rEPO-B and Darbepoetin-A (DARB) to determine the one 
who provides the most cost savings in treatment of anemia in patients with CKD on 
dialysis and not on dialysis. RESULTS: This pharmocoeconomic study suggests that 
rEPO-A therapy before dialysis may have a beneﬁcial impact on delaying progression 
to dialysis, reducing hospitalization time and the frequency of cardio-vascular com-
plications. The mean cost savings following the use of rEPO-A before dialysis were 
RUR471,834 (a10,782.3 for June 2009) per patient per year in comparison with 
control group. According to pharmacoeconomic evaluation the application of rEPO-A 
for treatment anemia leads to considerable cost savings in patients with CKD not on 
dialysis (RUR43,761(a1000) per patient per year more than DARB) and in patients 
with CKD on dialysis (RUR83,957(a1918.6) per patient per year more than rEPO-B 
and RUR66,769(a1525.8) per patient per year more than DARB). CONCLUSIONS: 
Correction of anemia with rEPO-A may reduce the utilization of health care resources 
and may lead to improved clinical and economic outcomes.
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OBJECTIVES: Intravenous immunoglobulin (IVIG )has demonstrated improvement 
in chronic inﬂammatory demyelinating polyneuropathy (CIDP) patients in placebo    
contolled trials. However, IVIG is also much more expensive than alternative treat-
ments such as corticosteroids. The objective of the paper is to evaluate, from a Cana-
dian perspective, the cost-effectiveness of IVIG compared to corticosteroid treatment 
of CIDP. METHODS: A markov model was used to evaluate the expected costs and 
QALYs for over 5 years for two treatments for CIDP 1) IVIG, and 2) corticosteroids. 
Patients in the IVIG treatment arm could respod or not respond respond or not 
